The isolated islet of Langerhans as a micro-organ and its transplantation to cure diabetes: Celebrating the legacy of Paul Lacy by Misler, Stanley
Washington University School of Medicine
Digital Commons@Becker
Presentations Center for History Of Medicine
2-19-2015
The isolated islet of Langerhans as a micro-organ
and its transplantation to cure diabetes: Celebrating
the legacy of Paul Lacy
Stanley Misler
Washington University School of Medicine in St. Louis
Follow this and additional works at: http://digitalcommons.wustl.edu/
historyofmedicine_presentations
This Presentation is brought to you for free and open access by the Center for History Of Medicine at Digital Commons@Becker. It has been accepted
for inclusion in Presentations by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Misler, Stanley, "The isolated islet of Langerhans as a micro-organ and its transplantation to cure diabetes: Celebrating the legacy of
Paul Lacy" (2015). Presentations. Paper 3.
http://digitalcommons.wustl.edu/historyofmedicine_presentations/3
The isolated islet of Langerhans as a 
micro-organ and its transplantation to 
cure diabetes mellitus:  
Celebrating the legacy of Paul Lacy. 
WUMS Historica Medica Lecture 43 
 February 19, 2015 
Stan Misler  
Paul E. Lacy, M.D., Ph.D 
(1924-2005) 
Late Kroc Professor Emeritus, 
Department of Pathology,    
Washington University Medical School 
Two careers in one: “I started my career wanting 
to learn about the structural basis and cell 
mechanics of insulin secretion and ended it with a 
mission to try to cure diabetes with islet 
transplantation.  Gosh, what a surprising turn a 
life in science can take!” 
“Grandpa Islet” 
Encourager, enabler, galvanized of others 
Proselytizer for islet transplantation: inspiring speaker and amazing gatherer of industrial 
grant support  
Asked “why not” when others more timid asked “wherefore and how” 
Personal legacy of openness and generosity of spirit as a mentor may be as important 
as his legacy to science 
 “Its time not to talk about what 
we’ve done because we’re only 
as good as the ideas we inspire” 
 
What hath Paul Lacy wrought? 
 
What followed him? 
1. The islet as micro-organ 
“As a pathologist, I believe what I see.” 
A. Pioneering islet microscopy: 
1. Characterization of a, b, d cell structure: 
b-cell identified by granule depletion on 
glucose and sulfonylurea stimulation and 
b-cell kill off by streptozytocin 
2. Conceptualization of granule 
“emiocytosis” (exocytosis) for hormone 
exit 
3. Recognition importance of granule 
maturation; roles of Ca in exocytosis & 
cytoskeleton in granule movement; 
preferential approach of granules to 
membrane after glucose stimulation;  
Dark field microscopy 
B. Lacy’s Gift: isolated islet of Langerhans 
Single islet cells & 
Cytosolic components of 
islet cells esp. hormone 
containing granules  
12-fold peak increase 
4-fold sustained decrease 
“Draw me a simple picture of what is 
happening between uptake of glucose 
and insulin secretion….and while 
you’re at it where are the sore spots in 
type 2 Diabetes (mellitus) ” 
C. Consensus model of operation of insulin- 
secreting b cell 
1. Glucose uptake by plasma membrane glucose 
transporters ->  
2. Oxidative metabolism of glucose, including by 
mitochondria, resulting in increased cytosolic 
ATP and decreased ADP -> 
3. Closure of ATP sensitive K channels, KATP  
against a background of open non-selective 
cation channels C(NS) -> 
4. Membrane depolarization -> 
5. Opening of voltage dependent ion channels 
including Ca channels -> 
6. Ca entry with binding to protein complex 
anchoring insulin granule to plasma 
membrane -> 
7. Fusion of insulin granule membrane with 
plasma membrane and exocytotic release of 
insulin granule contents. Also some release of 
GABA from smaller vesicles 
C(NS) KATP 
Inside-out excised patch 
1. A potassium channel (KATP) closed by bath applied 
glucose or sulfonylurea in cell attached patch of intact cell is 
also closed by bath applied ATP and reopened by bath 
applied ADP in the inside-out excised membrane patch  
Fluid stream 
Fluid stream 
Cell attached 
membrane 
patch 
Inside out excised 
membrane patch 
2. Stimulus – depolarization coupling in beta cells:  
glucose metabolism -> closure of KATP channels against 
background of non selective cation channels, C(NS) -> cell 
depolarization -> electrical activity due to sequential opening of Na, 
Ca and K channels  
Perforated 
patch mode 
before patch 
perforation  
Perforated 
patch mode 
after patch 
perforation  
3. Unraveling exocytosis in single b cells  
Exocytosis = incorporation of granule membrane into plasma 
membrane resulting in increased membrane capacitance (prop. 
surface area; measured by patch clamp mode) as well as 
simultaneous release of granule’s chemical contents sensed 
electrochemically (after preloading with serotonin) or seen as 
emptying of fluorescent marker (total internal reflectance 
fluorescence microscopy) 
   
Fluorescent marker 
Quantal release in b-cells as measured 
by capacitance increase (DCm) and 
amperometry (Iamp) 
Single action 
potentials  ->  
single granule 
exocytosis 
Prolonged 
depolarization   
->  release of 
10s of quanta 
4. Cellular basis of gut secreted incretin GLP-1  
and vagus nerve secreted Ach in enhancing 
glucose-induced insulin secretion:  
enhanced closure of KATP and recruitment of insulin 
granules for exocytosis 

6. Islet paracrine or “social” interactions 
b-cells at center of islet perfused first and secrete best when 
electrically coupled 
GABA released by b-cell contributes to depolarization-based 
inactivation of a-cell 
Somatostatin from d cells reduces secretion from b and a cells:      
G-protein coupled receptor and stimulation of phosphodiesterase  
7. Implications for Etiology of Type 2-DM 
(Ashcroft & Rorsman; Nicholls)  
T2DM, afflicting overweight and older persons 
with hyperglycemia, has been widely attributed to 
the “tune-out” of peripheral fat, muscle and liver 
cells to the effect of insulin thereby promoting 
hyperglycemia that was toxic to most cells.  
However newer evidence suggests that b-cell 
defects are important initiators of the phenotype.  
(i) Mutations that provide a gain of function of 
KATP (i.e., channels inherently less sensitive 
to ATP-induced closure) produce T2DM.  
Actual damage to b-cells can be prevented 
by normalizing insulin secretion with 
treatment with a sulfonylurea 
(ii) Day’s long exposure to high concentrations  
high free fatty acids such as palmitate results 
in disordering of tight coupling of Ca 
channels to insulin granules in IRP thus 
reducing depolarization – induced exocytosis 
(inc Cm) at unchanged calcium current 
------------>more hyperglycemic 
Control 
2. The isolated islet for transplantation 
Ricordi: Gartner innovation curve (or hype 
cycle) defining steps in evolution of clinical 
islet transplantation 
A. Lacy’s vision of “curative” islet  
transplantation in unstable Type I diabetes 
• “Islet greediness”: “Harvest pancreas’ worth of islets 
from a single human donor, purify them, and culture 
them to reduce their antigenicity  
•“Transplant islets into a safe location” in the 
recipient where they would take root and provide insulin 
independence, or at least eliminate the daily highs and 
lows of blood sugars  
•Strategies might be needed to prevent immune 
attacks to avoid long-term use of immuno-
suppressants 
B. Best guess as to Lacy’s basic 
assumptions underlying islet transplantation 
(i) Reduced model of islet function 
• b-cell-centricity: Need for moment-to-moment function of 
beta cells to secrete insulin to control blood glucose 
Hyperglycemic function of a-cells secondary concern and 
should be maintained as in perifusions 
Post Lacy: Restoration of C peptide secretion -> decreased 
neuropathy and increased myocardial and renal blood flow) 
• Innervation and incretins not essential: glucose-induced 
biphasic secretion seen in isolated, cultured islets.  However, 
incretins (e.g., synthetic analogs of GLP-1) might be used to 
enhance islet function in marginal cases 
• Islet cells poorly antigenic and if well treated may not 
need long term immunosuppression: limited antigenicity 
arises from passenger immune cells and endothelium 
• Islet cells intrinsically plastic: hypertrophy and 
replacement of worn-out cells occurs in intact islets 
(ii) Ease of islet transplantation as compared 
with whole pancreas transplantation 
• Many choices of target sites: subcapsular in kidney or 
spleen; intraperitoneal; but especially intrahepatic via 
injection/embolization into portal vein to provide first 
pass source of insulin for hepatocytes 
• Whole pancreas Tx complicated by high M/M 
• No need for exocrine drainage.  
 
C. Proof of principle 
(Ballinger, Scharp and Lacy, 1973) 
 Syngeneic islet transplantation: 400-600 islets into 
portal veins of streptozotocin-treated, single dose 
immunosuppressed rats ->  
 2-12 weeks: abolition of polydypsia, polyuria and post-
prandial hyperglycemia; establishment of near normal 
resting glucose and insulin levels; and reversal of 
histological lesions of mesenteric autonomic nerve 
supply 
 5 months: well granulated intrahepatic beta and alpha 
cells forming direct contacts with hepatocytes 
D. “Trigger technology” = high yield isolation of 
islets from pancreati of large mammals 
Collagenase 
digestion of 
pancreas helped by 
marbles pounding  
whole pancreas 
1. Procedure: Isolation of 
islets from pancreata                          
and infusion into liver via 
percutaneous transhepatic 
catheterization of portal 
vein under fluoroscopic or 
ultrasound guidance  
E. Clinical islet transplantation at the “peak 
of inflated expectations” beginning in 1990 
Portogram of 
injection 
MRI showing 
engraftment 
(steatosis = 
local fatty liver) 
Courtesy: D. Brennan, WUMC 

2. First 15 years of trials, the best results -> 
“trough of disillusionment” 2005 
• Edmonton + Miami + Minnesota 
• Type 1 DM  X 25 years; hypoglycemic episodes but no renal dysfunction 
• Semi-selected pancreati (ABO but not HLA compatible donors without history 
of DM); cold ischemia < 12h 
• Initial transplant 400,000 islet equivalents (IE) (5 cc), 0-2 boosters -> average 
total 800,000 IE; later 10,000 -14,000 IE /kg body weight 
• Induction with antiCD25 antibody (later strong lymphodepleting induction) and 
steroid free immunosuppression with low dose calcineurin inhibitor and high 
dose mTOR inhibitor; more recently conversion to mycophenolate acid to 
avoid nephrotoxicity 
• 82% insulin dependent at 1 yr; 20% at 5 years (82% graft survival by C-pep) 
• Better glycemic control (HbA1c 7 vs. 9) with fewer episodes of hypoglycemia 
even if not insulin-dependent after transplant of “marginal” tissue 
• Chronic complications: mouth ulcers, anemia, diarrhea, ovarian cysts, acne, 
increased need for antihypertensives, statins 
• Unsolved: peripheral/autonomic neuropathy; hypoglycemic counter-
regulation/awareness  
F. Overcoming the myopia in early transplant 
vision or “the slope of enlightenment”  
Initially little intimate knowledge or standardization of the 
islet as a micro-organ.  
(a) A priori, metabolic state of transplanted islets should determine 
their long-term survival and should be dependent on: (i) condition of 
source pancreas and islets and (ii) stability of islets as micro-organ 
out of their pancreatic milieu 
(b) However there was continued reliance on pre-transplant 
optical measures of immediate “viability”, “gentle standards” for 
quantitation of yield (what is an IE?) and for “in vitro” secretion 
after acute culture (2-3 fold increase).    
Little or no extensive post-transplant assays of “in vivo” 
functional reserve (e.g., C peptide secretion) 
 G. Complex pre-transplant issues: 
Dependence on source and early treatment   
(a) Pre-harvest of pancreas: donor age, adiposity, insulin reserve, 
& cytokine storm in brainstem death 
Conundrum: islets of lean & <35y/o -> difficult to liberate but likely robust islets 
vs. islets of obese & > 50 -> large, encapsulated, easy to liberate islets 
with less function  
(b) Post-harvest of pancreas and pre-isolation of islets: cold 
ischemia time usually > optimum 6-8 h (“left-over organs”); 
fluorocarbon O2 transport solution 
(c) Continuing problems of isolation: enzyme potency and 
exposure time  
(d) Post-isolation: shaggy vs. round; fresh vs. cultured  
(e) Newer developments for rapid pre-transplant islet screening: 
Laser scanning cytometry; mitochondrial membrane potential 
assay; tests of increased O2 consumption with glucose 
stimulation 
Islet transplants into liver 
survive less well than those 
infused into pancreas:                         
(i) decreased glucose oxidation 
and insulin secretion;                        
(ii) down-regulation of 
expression of genes of 
differentiation;                           
(iii) reduced probability of islet 
cell replacement by local stem 
cells and budding pancreatic 
ducts 
H. Complex post-transplant issues:                   
1. “Stranger in a strange hepatic land”-> acute 
and chronic loss of tissue and function 
2. Attacking islet ischemia and poor post-
transplant proliferation 
(a) 30% of islets have necrotic cores at time of infusion -> need for 
 non-ischemic preparation 
(b) Loss of 30-40% of viable islets by “hypoxia-reperfusion injury” 
 -> ischemia  Inhibitable by nicotinamide  
(c) Rapid onset of apoptosis (including lymphocyte induced)  + a, b -> 
loss of 80% of islets in 3 days. 
 Inhibition by ex vivo transduction of islets with X-linked inhibitor 
of apoptosis ? 
(d) Poor acute and long-term functional revascularization and 
oxygenation 
 Intra-islet pO2 = 5-10 torr vs. 40 torr in situ -> switch to anerobic 
respiration with poor stimulus-evoked secretion. No current treatment 
(e) Poor islet cell proliferation Improved by transduction of 
proliferation switch -> activation of Jak-Stat pathway by 
membrane permeant agonists?  
 
 
I. Success with alternative transplantation 
modalities: lessons learned  
• Freshly prepared, partially purified pancreatic tissue 
infused into portal vein results in long-term (up to 13 
year) reduction in fasting glucose and HBA1c; correlated 
with mass of infused tissue.  
 Implies that mass of co-transplanted acinar and ductal 
 tissue not an impediment 
• Solitary pancreatic transplantation or simultaneous with 
renal transplantation results in 70-80% survival of 
pancreatic function up to 3 years (Improvement due to 
reduced exocrine damage during harvest; bladder drainage 
of ductal secretion; tacrolimus-based immunosuppression). 
 Implies that immunosuppression is not a swift and potent 
 islet killer 
J. The future 
1. Finding a better microenvironment for islet 
transplantation: the bone marrow?  
“Who would have thunk it ?” 
2. Human islet transplantation likely to be superseded   
by a bioengineering approach…. but which? 
• Chemical engineering of encapsulation with alginate: xenogenic 
porcine microencapsulation followed by (i) intraperitoneal injection or 
(ii) macro or hollow fiber encapsulation with subcutaneous patch 
implantation. This should avoid immunosuppression and in 
xenotransplant should protect against foreign oncogenes, viruses 
while still susceptible to macrophage attack. 
• Developmental engineering: induction of embryonic stem cells (ES 
= inner cell mass of preimplantation blastocysts) or pleuripotential 
stem cells (iPS) for differentiation along b-cell lineage 
• Cell engineering (transdifferentiation): directed transdifferentiation 
of hepatic and pancreatic exocrine ductal cells or acinar cell line 
reprogramming of these by adenovirus mediated transduction of 
PDX1 and NGN3, MAFA for ectopic expression  
• Whole organ bioengineering: pancreatic extracellular matrix (ECM) 
with signaling molecules and growth factors to drive cellular 
repopulation, and enhance islet secretion and survival.  Mimicable by 
biomolecular carriers? 
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